Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | MARK3 | P27448 | 1/20 | 0.37 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.37 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 4/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | BUB1 | O43683 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8312657 | 0.88 | GPR119 (0.36) | PIM1MARK3MAP4K2CAMK2BPIM3 | |
| SCHEMBL16060936 | 0.86 | PIM1 (0.36) | PIM1MARK3MAP4K2CAMK2BPIM3 | |
| SCHEMBL20864185 | 0.86 | FAAH (0.43) | PIM1MARK3MAP4K2CAMK2BPIM3 | |
| SCHEMBL6555080 | 0.84 | PIM1 (0.35) | PIM1MARK3MAP4K2CAMK2BPIM3 | |
| SCHEMBL2789678 | 0.82 | NR1H2 (0.38) | PIM1MARK3MAP4K2CAMK2BPIM3 | |
| SCHEMBL15874826 | 0.79 | TBXAS1 (0.46) | PIM1MARK3MAP4K2CAMK2BPIM3 | |
| SCHEMBL7654635 | 0.78 | PIM1 (0.39) | PIM1MARK3MAP4K2CAMK2BPIM3 | |
| SCHEMBL406298 | 0.78 | ATM (0.38) | — | |
| SCHEMBL9516130 | 0.77 | PIM1 (0.38) | PIM1MARK3MAP4K2CAMK2BPIM3 | |
| SCHEMBL6950813 | 0.77 | BCHE (0.32) | PIM1MARK3MAP4K2CAMK2BPIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9550757-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9550757-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2017-01-24 | — | — | US | disclosed |
| EP-2542089-B1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2017-01-18 | — | — | EP | disclosed |
| US-20140155370-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2014-06-05 | — | — | US | disclosed |
| US-20140155370-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2014-06-05 | — | — | US | disclosed |
| US-8513230-B2 | Nuclear transport modulators and uses thereof | KARYOPHARM THERAPEUTICS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513230-B2 | Nuclear transport modulators and uses thereof | KARYOPHARM THERAPEUTICS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20110275607-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275607-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| WO-2011109799-A1 | NUCLEAR TRANSPORT MODULATIORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
| EP-1888512-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006133216-A2 | 4-SUBSTITUTED ARYLAMINE DERIVATIVES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-14 | — | — | WO | disclosed |
| EP-0903347-B1 | NOVEL CYCLIC DEPSIPEPTIDE PF1022 DERIVATIVES | MEIJI SEIKA KAISHA (JP) | 2005-07-20 | — | — | EP | disclosed |
| CN-1082051-C | Novel cyclic depsipeptide PF1022 derivatives | MEIJI SEIKA CO (JP) | 2002-04-03 | — | — | CN | disclosed |
| US-6329338-B1 | CYCLIC OLIGOPEPTIDE TETRAESTES | MEIJI SEIKA KAISHA, LTD. (JP) | 2001-12-11 | — | — | US | disclosed |
| EP-0903347-A1 | NOVEL CYCLIC DEPSIPEPTIDE PF1022 DERIVATIVES | MEIJI SEIKA KAISHA LTD. (JP) | 1999-03-24 | — | — | EP | disclosed |
| CN-1201456-A | Novel cyclic depsipeptide PF1022 derivatives | MEIJI SEIKA CO (JP) | 1998-12-09 | — | — | CN | disclosed |
| US-5173496-A | Antiinflammatory agents | ICI PHARMA (FR) | 1992-12-22 | — | — | US | disclosed |
| EP-0284174-B1 | THERAPEUTIC PREPARATIONS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-07-29 | — | — | EP | disclosed |
| EP-0284174-A1 | Therapeutic preparations | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140155370-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, NXF1, XPOT | PIM1 3173/4885MARK3 1362/4885MAP4K2 897/4885 |
| US-20110275607-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, NXF1, XPOT | PIM1 3173/4885MARK3 1362/4885MAP4K2 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.